Princeton, N.J. — Bristol Myers Squibb said it plans to invest about $2.3 billion in a new pharmaceutical manufacturing campus in Houston that is expected to create nearly 500 permanent jobs.
The approximately 600,000-square-foot facility will be built at Generation Park and is part of the company’s previously announced commitment to invest $40 billion in U.S. research and development, technology and manufacturing over five years.
Bristol Myers Squibb said the Houston campus will be designed to manufacture several types of medicines, including small-molecule drugs, biologics and antibody-drug conjugates. The facility will support drug product and finished-goods manufacturing from late-stage development through commercial launch.
The modular design will allow the company to add or reconfigure manufacturing capacity as its drug pipeline and commercial needs change.
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
The company said Houston was selected following a competitive evaluation of several markets in the Central and Eastern United States. Factors included the region’s life sciences workforce, available economic incentives, transportation and utility infrastructure and business environment.
Texas Gov. Greg Abbott said the investment reflects the growth of the state’s biotechnology and life sciences sector and its workforce.
Bristol Myers Squibb expects the campus to initially employ nearly 500 people in positions including manufacturing operations, engineering, maintenance, quality control and assurance, and administration.
The company also expects construction of the facility to support about 2,000 construction and other indirect jobs between 2027 and 2030.
Karin Shanahan, Executive Vice President and Chief Supply Chain and Operations Officer at Bristol Myers Squibb, said the campus will combine modular manufacturing with advanced digital capabilities to improve production flexibility and supply reliability.
The company said the facility is being designed to accommodate future automation and digital manufacturing technologies and could expand beyond its initial configuration over time.
Bristol Myers Squibb already works with a contract manufacturer in Texas for commercial and clinical-trial production. The company also operated 250 clinical trial sites in the state in 2025.
Bristol Myers Squibb said it invested approximately $10 billion in research and development in 2025 as it continues to develop new medicines across its portfolio.
